Temozolomide
Temozolomide is an orally administered alkylating agent that is being increasing used especially for malignant gliomas.
Dosage
Concurrent with radiotherapy: 75 mg/m2 daily during radiotherapy course
Adjuvant treatment for grade III and IV glioma: 6 - 12 monthly cycles 5 days on/23 days off 150 mg/m2.